Insilico Medicine is a clinical-stage biotechnology company harnessing generative AI to discover and develop novel therapeutics. Its platform integrates biology, chemistry, and medicine, enabling rapid target discovery and molecular generation. With a strong scientific foundation and enterprise-grade AI systems, the company collaborates with global pharma partners while advancing its own drug pipeline. Insilico serves oncology, fibrosis, infectious diseases, neurodegeneration, and autoimmune conditions, positioning itself as one of the leading AI-native drug discovery companies.
What Is Insilico Medicine and What Does It Do?
Insilico Medicine, founded in 2014 by Alex Zhavoronkov, is a generative AI drug discovery and clinical-stage biotechnology company headquartered in Hong Kong and New York. It develops AI platforms that integrate deep generative models, transformers, and reinforcement learning to design novel targets and molecules for multiple disease areas. Insilico Medicine employs between 501-1000 employees. The company also advances its internal drug candidates, operates automated robotic labs, and collaborates on high-value partnerships with global pharmaceutical companies.
How Much Funding Has Insilico Medicine Raised?
1. Series E
- Amount Raised: $110M
- Lead Investors: Value Partners Group
- Motivation: To advance AI platform development, expand automated labs, and progress clinical trials.
2. Series G (2020)
- Amount Raised: $200M
- Lead Investors: Google, Novo Holdings, Baillie Gifford, Franklin Templeton, T. Rowe Price
- Motivation: To scale its drug pipeline and accelerate generative AI R&D.
Total Funding Raised: $1.05 Billion
Current Valuation: $8.1 Billion
Latest Funding Date: 2025 (Series E)
Key Investors
1. Value Partners Group
- Details: Major Asia-based investment firm leading the latest Series E.
- Investment Focus Areas: Public and private equity, healthcare, technology.
- Notable Investments: Insilico Medicine.
2. Baillie Gifford
- Details: Global long-term investor supporting major life sciences and AI companies.
- Investment Focus Areas: AI, biotech, consumer tech.
- Notable Investments: Tesla, Amazon, Moderna, Insilico Medicine.
3. T. Rowe Price
- Details: Leading fund manager investing globally in high-growth companies.
- Investment Focus Areas: Biotech, technology, healthcare.
- Notable Investments: Tempus, Allbirds, Insilico Medicine.
Where Is Insilico Medicine’s Headquarters?
Insilico Medicine is headquartered in Hong Kong with major U.S. operations in New York. The location provides proximity to global pharmaceutical companies, access to Asia-Pacific R&D markets, and strong cross-border collaboration opportunities.
What’s Next for Insilico Medicine?
Insilico plans to accelerate clinical validation of its key fibrosis drug candidate, expand co-development partnerships, and scale its automated robotic lab infrastructure. With rapidly improving generative AI capabilities, it aims to shorten drug development cycles and expand into new therapeutic areas. Its strong investor backing positions it to push deeper into multimodal AI, real-world clinical data integration, and pharmaceutical-grade automation.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Insilico Medicine. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
